Aurora Spine to Host ZOOM Call with Alpha Wolf Trading CEO Tim Weintraut
11 September 2024 - 1:30PM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, is excited to
announce a recorded ZOOM call on September 13, 2024 with Trent
Northcutt, CEO of Aurora Spine, and Tim Weintraut, CEO
of Alpha Wolf Trading/Blog. The conversation will focus on
Aurora's latest innovations, exciting clinical results, and the
company's continued financial success.
Key Discussion Points Include:
- DEXA™
Technology – Aurora's cutting-edge, patient-specific
interbody implant technology designed to optimize spinal surgery
outcomes.
- New Product
Launches – Introducing the New
Hydra and Osteo-Onyx Lumbar Screw Systems (Degen,
Scoli/Deformity, and MIS), advancing the precision and reliability
of spinal fixation with proprietary HYDRA
RST™ (Roughened Surface Technology). Pioneering
complex spine, trauma, deformity, and minimally invasive spinal
systems.
- ZIP™ Multi-Center Study
Results – Showcasing the impressive outcomes from the
ZIP study, further validating Aurora’s ZIP™ technology as a
breakthrough in minimally invasive spine procedures.
- SiLO™ TFX SI Joint Fusion
System – Now the fastest-growing product in Aurora’s
portfolio, the SiLO TFX system continues to gain traction within
the pain management market.
Financial and Business Highlights:
- Continued Positive
EBITDAC – Q2 2024 EBITDAC stood at $105,522, a
significant improvement from ($163,660) in Q2 2023, marking a
positive swing of $269,182. This achievement represents the fourth
consecutive quarter of positive EBITDAC, underscoring Aurora’s
sustained profitability.
- Robust Sales
Growth – Q2 2024 sales reached $4,079,543, an
increase of $510,960 or 14.3% compared to $3,568,583 in Q2 2023.
This marks the third consecutive quarter with revenue surpassing $4
million, driven by demand for Aurora’s advanced spine
solutions.
- Enhanced Profit
Margins – Q2 gross margin improved to 62.4%, a 5.5%
increase from the 56.9% margin in Q2 2023. This growth was fueled
by the increased sales of higher-margin implants, alongside lower
distributor commissions.
- Surge in SiLO™
Sales – The SiLO™ TFX SI joint fusion system and
allograft implants generated $1.7 million in sales, accounting for
41.7% of Q2 revenue, a significant jump from $795K (22.3% of
revenue) in Q2 2023. Sales of the SiLO™ TFX system grew by 20.4%
from Q1 to Q2 2024, marking Aurora’s expansion into the pain
management market.
- ZIP™ 51 Sales
Double – The ZIP™ 51 implant sales nearly doubled in
Q2 2024, reaching $669,316, a 93.7% increase from $345,505 in Q2
2023, driven by strong marketing efforts and increased surgeon
adoption.
- Expanding Sales
Force – Aurora continues to scale its sales team,
which contributed to its sales growth. New additions to the sales
force are expected to onboard more surgeons into Aurora’s expanding
ecosystem.
- Advanced Training
Initiatives – Aurora remains committed to excellence
by hosting advanced training sessions and cadaver labs for top
orthopedic, neurosurgical, and pain management physicians,
demonstrating the clinical advantages of the ZIP™ and SiLO™
systems.
"We’re extremely proud of the innovations we’ve brought to
market, including our SiLO™ TFX system and the exciting new
developments in our Hydra and Osteo-Onyx lumbar screw systems”,
said Trent Northcutt, President and CEO of Aurora Spine. “Our
consistent financial growth, along with the strong clinical
outcomes of our products, reflects the hard work and dedication of
our entire team. We're committed to continuing this momentum and
delivering cutting-edge solutions to improve patient care and
outcomes in the spine and pain management markets."
This ZOOM call is a must-watch for investors, healthcare
professionals, and anyone interested in Aurora Spine’s future
trajectory. The recorded session will be available on Alpha
Wolf Trading’s blog shortly after the event. Visit Alpha
Wolf Trading's blog for more details
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal
implant and pain markets through a series of innovative, minimally
invasive, regenerative spinal implant technologies. Aurora Spine is
an emerging growth company focused on bringing new solutions to the
spinal implant and pain care markets through a series of screwless,
innovative, minimally invasive, regenerative spinal implant
technologies. Additional information can be accessed at
www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company’s products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any statements that express, or involve discussions
as to, expectations, beliefs, plans, objectives, assumptions or
future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and
uncertainties which could cause actual results or outcomes to
differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out
herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this
press release and Aurora Spine does not assume any obligation to
update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine CorporationTrent NorthcuttPresident and Chief
Executive Officer(760) 424-2004
Chad ClouseChief Financial Officer(760)
424-2004www.aurora-spine.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Okt 2023 bis Okt 2024